| Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. | |
| | |
MedLine Citation:
|
PMID: 17097190 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Nucleic acids have gained a lot of interest for the treatment of ocular diseases. The first to enter in clinic has been Vitravene an antisense oligonucleotide for the treatment of cytomegalovirus (CMV) infection and more recently, research on aptamers have led to the marketing of anti-vascular endothelial growth factor (VEGF) inhibitor (Macugen) for the treatment of age-related macular degeneration (AMD). The siRNAs appear very promising as they are very potent inhibitors of protein expression. Despite their potential, nucleic acids therapeutic targets of nucleic acid-based drugs are mainly located in the posterior segment of the eye requiring invasive administration which can be harmful if repeated. Their intracellular penetration in some cases needs to be enhanced. This is the reason why adequate delivery systems were designed either to insure cellular penetration, protection against degradation or to allow long-term delivery. A combination of both effects was also developed for an implantable system. In conclusion, the intraocular administration of nucleic acids offers interesting perspectives for the treatment of ocular diseases. |
| | |
Authors:
|
Elias Fattal; Amélie Bochot |
Publication Detail:
|
Type: Journal Article; Review Date: 2006-09-15 |
Journal Detail:
|
Title: Advanced drug delivery reviews Volume: 58 ISSN: 0169-409X ISO Abbreviation: Adv. Drug Deliv. Rev. Publication Date: 2006 Nov |
Date Detail:
|
Created Date: 2006-11-27 Completed Date: 2007-02-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8710523 Medline TA: Adv Drug Deliv Rev Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1203-23 Citation Subset: IM |
Affiliation:
|
UMR CNRS 8612, School of Pharmacy, Université Paris Sud, Châtenay-Malabry, France. elias.fattal@cep.u-psud.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Aptamers, Nucleotide / administration & dosage*, metabolism Drug Delivery Systems* Eye Diseases / drug therapy*, metabolism Humans Oligonucleotides, Antisense / administration & dosage*, metabolism RNA, Small Interfering / administration & dosage*, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Aptamers, Nucleotide; 0/Oligonucleotides, Antisense; 0/RNA, Small Interfering |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mathematical modeling and simulation of drug release from microspheres: Implications to drug deliver...
Next Document: Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.